In this episode of Healthy Returns, we sit down with Stewart Bartlett, CEO of Ferronova, to explore how innovative imaging technology is transforming cancer surgery. Stewart shares insights into how Ferronova's nanoparticle-based approach can improve patient outcomes, reduce overtreatment, and potentially save lives.

Key Topics:

• The unmet needs in oesophageal and stomach cancer treatment
• How Ferronova's iron oxide nanoparticle technology works during surgery
• The significance of lymph node mapping in cancer metastasis
• Results from clinical trials with 100% accuracy in identifying targeted lymph nodes
• Regulatory roadmap in Australia and Europe, expecting approval in 3-4 years
• Market potential driven by healthcare economics, with treatment recurrence costs reaching $430,000 in the US
• Competitive landscape and comparison to radiopharmaceutical diagnostics

Timestamps:
00:00 - Introduction and episode overview
00:27 - Stewart Bartlett's background in engineering and medtech
01:05 - Ferronova's focus on precision imaging for cancer surgery
01:44 - The origin of Ferronova from university research
02:11 - Unmet needs in oesophageal and stomach cancer treatments
02:52 - The nanoparticle technology for lymph node mapping
03:48 - Overcoming challenges of chemotherapy and radiotherapy
04:11 - MRI visibility and magnetic detector during surgery
04:54 - Surgical application of Ferronova's device
05:16 - How the system targets and drains lymph nodes
05:45 - Clinical trial progress and accuracy results
06:23 - Next steps and timeline for regulatory approval
06:58 - Estimated timeframe of three to four years for market readiness
07:49 - Market potential and economic benefits of reducing recurrence costs
08:23 - Comparison with radiopharmaceutical diagnostics
09:02 - Final thoughts and closing

Resources & Links:

• Ferronova Official Website
• Iron Oxide Nanoparticles Explained
• Clinical Trials Data

 --ENDS--